Global Oncogene-Targeted Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Oncogene-Targeted Drugs market size was valued at US$ 66452 million in 2025 and is forecast to a readjusted size of US$ 109166 million by 2032 with a CAGR of 7.3% during review period.
Oncogene-Targeted Drugs are antineoplastic medicines designed to act on oncogenic driver alterations and their encoded proteins, receptors, or downstream signaling pathways that play a critical role in tumor initiation, maintenance, and progression. They include small-molecule targeted agents and biologic products; the former are commonly formulated as tablets, capsules, or injectables, whereas the latter are typically injectable monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates. Their composition generally consists of an active pharmaceutical ingredient, excipients, and a suitable dosage-form system, and some products are used together with companion diagnostics. By selectively inhibiting abnormalities involving EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 and related drivers, these drugs block signaling required for cancer-cell proliferation, survival, angiogenesis, or metastasis, thereby improving therapeutic precision and reducing nonselective damage to normal tissues. They are widely used in molecularly defined solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma, as well as selected hematologic malignancies.
The industry position of Oncogene-Targeted Drugs is evolving from a specialized category within oncology therapeutics into a core value node of the precision medicine ecosystem. The primary opportunity comes from the ongoing shift in cancer care from tumor-type-based treatment to molecularly stratified treatment. An increasing number of clinical decisions are now built around the identification of driver alterations such as EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, and HER2, which means these drugs are no longer merely therapeutic end products. Instead, they are becoming part of a high-barrier solution set that integrates genomic testing, companion diagnostics, data interpretation, patient stratification, and real-world evidence. The NCI defines targeted therapy as treatment directed at specific changes that help cancer cells grow, spread, and survive, while the FDA recognizes companion diagnostics as essential to the clinical use of multiple oncology targeted therapies. This gives the segment value far beyond product revenue alone, extending into precision-use efficiency, pathway optimization, and stronger health-economic justification. For companies, the most attractive opportunity lies not in a single asset, but in building platform-based portfolios around advantaged targets, resistance management, combination regimens, and global registration strategies. For investors, the long-term appeal of this market lies in its unique combination of innovation intensity, clinically testable value, and commercial scalability. For policymakers, it represents a strategic lever for upgrading advanced biopharma, molecular diagnostics, and standardized oncology management.
At the same time, this market is not expanding in a linear manner. It is a classic high-R&D, high-regulation, high-competition arena where challenges and risks remain substantial. Commercial success is highly dependent on target validity and accurate patient selection; if the truly addressable patient pool proves smaller than expected, or if companion diagnostic penetration lags, market uptake can be materially constrained. Resistance is another structural challenge: early efficacy rarely guarantees durable positioning, and companies must continuously invest in next-generation molecules, combination strategies, and indication expansion or risk being displaced by new mechanisms. The barriers are not confined to discovery either; they extend across CMC, GMP, multi-region regulatory approval, pharmacovigilance, supply resilience, and reimbursement negotiations. This is especially relevant as more complex molecular modalities such as monoclonal antibodies, bispecifics, and ADCs expand within oncology. In this environment, manufacturing consistency, quality control, and global commercial delivery capability are becoming decisive competitive variables. More importantly, as biomarker-driven development becomes an industry norm, competition is shifting from a race to launch toward a race to build evidence loops, clinical consensus, and access advantages. Companies lacking integrated clinical development capability, diagnostic partnership depth, and international market access expertise will find it increasingly difficult to sustain leadership in high-value niches.
On the demand side, future growth is likely to be driven more by structural upgrading than by volume expansion alone. Hospitals and clinicians increasingly expect these therapies not only to improve response rates, but also to support earlier intervention, more precise stratification, longer survival benefit, and more manageable safety profiles. This is pushing usage from late-stage salvage settings toward adjuvant, neoadjuvant, perioperative, and maintenance settings. At the same time, payers and health systems are moving beyond innovation labels and focusing more closely on real-world outcomes, post-resistance treatment pathways, testing accessibility, and total cost of care. As a result, products that are tightly linked with companion diagnostics, supported by clear patient-selection logic, and embedded into standardized treatment pathways will be better positioned to sustain demand. The downstream customer landscape is also broadening. In addition to major cancer centers, regional hospitals, specialist networks, molecular pathology laboratories, and precision medicine service platforms are playing a larger role, prompting drug makers to move beyond conventional academic promotion toward integrated go-to-market models built around therapeutics, diagnostics, education, and patient management. Overall, demand fundamentals for oncogene-targeted drugs are expected to remain resilient, but the next phase of market deepening will be driven not by conceptual innovation alone, but by system-level solutions capable of balancing molecular diagnostics, therapeutic benefit, accessibility, and commercial reproducibility.
This report is a detailed and comprehensive analysis for global Oncogene-Targeted Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncogene-Targeted Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Oncogene-Targeted Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Oncogene-Targeted Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Oncogene-Targeted Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oncogene-Targeted Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncogene-Targeted Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncogene-Targeted Drugs, with revenue, gross margin, and global market share of Oncogene-Targeted Drugs from 2021 to 2026.
Chapter 3, the Oncogene-Targeted Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Oncogene-Targeted Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncogene-Targeted Drugs.
Chapter 13, to describe Oncogene-Targeted Drugs research findings and conclusion.
Oncogene-Targeted Drugs are antineoplastic medicines designed to act on oncogenic driver alterations and their encoded proteins, receptors, or downstream signaling pathways that play a critical role in tumor initiation, maintenance, and progression. They include small-molecule targeted agents and biologic products; the former are commonly formulated as tablets, capsules, or injectables, whereas the latter are typically injectable monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates. Their composition generally consists of an active pharmaceutical ingredient, excipients, and a suitable dosage-form system, and some products are used together with companion diagnostics. By selectively inhibiting abnormalities involving EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 and related drivers, these drugs block signaling required for cancer-cell proliferation, survival, angiogenesis, or metastasis, thereby improving therapeutic precision and reducing nonselective damage to normal tissues. They are widely used in molecularly defined solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma, as well as selected hematologic malignancies.
The industry position of Oncogene-Targeted Drugs is evolving from a specialized category within oncology therapeutics into a core value node of the precision medicine ecosystem. The primary opportunity comes from the ongoing shift in cancer care from tumor-type-based treatment to molecularly stratified treatment. An increasing number of clinical decisions are now built around the identification of driver alterations such as EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, and HER2, which means these drugs are no longer merely therapeutic end products. Instead, they are becoming part of a high-barrier solution set that integrates genomic testing, companion diagnostics, data interpretation, patient stratification, and real-world evidence. The NCI defines targeted therapy as treatment directed at specific changes that help cancer cells grow, spread, and survive, while the FDA recognizes companion diagnostics as essential to the clinical use of multiple oncology targeted therapies. This gives the segment value far beyond product revenue alone, extending into precision-use efficiency, pathway optimization, and stronger health-economic justification. For companies, the most attractive opportunity lies not in a single asset, but in building platform-based portfolios around advantaged targets, resistance management, combination regimens, and global registration strategies. For investors, the long-term appeal of this market lies in its unique combination of innovation intensity, clinically testable value, and commercial scalability. For policymakers, it represents a strategic lever for upgrading advanced biopharma, molecular diagnostics, and standardized oncology management.
At the same time, this market is not expanding in a linear manner. It is a classic high-R&D, high-regulation, high-competition arena where challenges and risks remain substantial. Commercial success is highly dependent on target validity and accurate patient selection; if the truly addressable patient pool proves smaller than expected, or if companion diagnostic penetration lags, market uptake can be materially constrained. Resistance is another structural challenge: early efficacy rarely guarantees durable positioning, and companies must continuously invest in next-generation molecules, combination strategies, and indication expansion or risk being displaced by new mechanisms. The barriers are not confined to discovery either; they extend across CMC, GMP, multi-region regulatory approval, pharmacovigilance, supply resilience, and reimbursement negotiations. This is especially relevant as more complex molecular modalities such as monoclonal antibodies, bispecifics, and ADCs expand within oncology. In this environment, manufacturing consistency, quality control, and global commercial delivery capability are becoming decisive competitive variables. More importantly, as biomarker-driven development becomes an industry norm, competition is shifting from a race to launch toward a race to build evidence loops, clinical consensus, and access advantages. Companies lacking integrated clinical development capability, diagnostic partnership depth, and international market access expertise will find it increasingly difficult to sustain leadership in high-value niches.
On the demand side, future growth is likely to be driven more by structural upgrading than by volume expansion alone. Hospitals and clinicians increasingly expect these therapies not only to improve response rates, but also to support earlier intervention, more precise stratification, longer survival benefit, and more manageable safety profiles. This is pushing usage from late-stage salvage settings toward adjuvant, neoadjuvant, perioperative, and maintenance settings. At the same time, payers and health systems are moving beyond innovation labels and focusing more closely on real-world outcomes, post-resistance treatment pathways, testing accessibility, and total cost of care. As a result, products that are tightly linked with companion diagnostics, supported by clear patient-selection logic, and embedded into standardized treatment pathways will be better positioned to sustain demand. The downstream customer landscape is also broadening. In addition to major cancer centers, regional hospitals, specialist networks, molecular pathology laboratories, and precision medicine service platforms are playing a larger role, prompting drug makers to move beyond conventional academic promotion toward integrated go-to-market models built around therapeutics, diagnostics, education, and patient management. Overall, demand fundamentals for oncogene-targeted drugs are expected to remain resilient, but the next phase of market deepening will be driven not by conceptual innovation alone, but by system-level solutions capable of balancing molecular diagnostics, therapeutic benefit, accessibility, and commercial reproducibility.
This report is a detailed and comprehensive analysis for global Oncogene-Targeted Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncogene-Targeted Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Oncogene-Targeted Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Oncogene-Targeted Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Oncogene-Targeted Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Oncogene-Targeted Drugs
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oncogene-Targeted Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Axitinib (Inlyta)
- Ponatinib (Iclusig)
- Imatinib (Gleevec)
- Sunitinib (Sutent)
- Pazopanib (Votrient)
- Dabrafenib (Tafinlar)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
- Cabozantinib (Cabometyx and Cometriq)
- Sorafenib (Nexavar)
- Chemical Synthesis Product
- Semi-Synthetic Product
- Recombinant Expression Product
- Cell-Culture Derived Product
- Enzymatic Synthesis Product
- Oligonucleotide Solid-Phase Synthesis Product
- Conjugation Process Product
- Bottle Presentation
- Blister Presentation
- Vial Presentation
- Ampoule Presentation
- Prefilled Syringe Presentation
- Cartridge Presentation
- Infusion Bag Presentation
- Clinic
- Hospital
- Others
- Johnson & Johnson
- Roche
- Pfizer
- AstraZeneca
- Eli Lilly
- Novartis
- Bristol Myers Squibb
- Bayer
- Takeda
- Amgen
- Boehringer Ingelheim
- Daiichi Sankyo
- Hengrui
- Hansoh
- Betta
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncogene-Targeted Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncogene-Targeted Drugs, with revenue, gross margin, and global market share of Oncogene-Targeted Drugs from 2021 to 2026.
Chapter 3, the Oncogene-Targeted Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Oncogene-Targeted Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncogene-Targeted Drugs.
Chapter 13, to describe Oncogene-Targeted Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oncogene-Targeted Drugs by Type
1.3.1 Overview: Global Oncogene-Targeted Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Oncogene-Targeted Drugs Consumption Value Market Share by Type in 2025
1.3.3 Axitinib (Inlyta)
1.3.4 Ponatinib (Iclusig)
1.3.5 Imatinib (Gleevec)
1.3.6 Sunitinib (Sutent)
1.3.7 Pazopanib (Votrient)
1.3.8 Dabrafenib (Tafinlar)
1.3.9 Vandetanib (Caprelsa)
1.3.10 Vemurafenib (Zelboraf)
1.3.11 Cabozantinib (Cabometyx and Cometriq)
1.4 Classification of Oncogene-Targeted Drugs by Manufacturing Process
1.4.1 Overview: Global Oncogene-Targeted Drugs Market Size by Manufacturing Process: 2021 Versus 2025 Versus 2032
1.4.2 Global Oncogene-Targeted Drugs Consumption Value Market Share by Manufacturing Process in 2025
1.4.3 Chemical Synthesis Product
1.4.4 Semi-Synthetic Product
1.4.5 Recombinant Expression Product
1.4.6 Cell-Culture Derived Product
1.4.7 Enzymatic Synthesis Product
1.4.8 Oligonucleotide Solid-Phase Synthesis Product
1.4.9 Conjugation Process Product
1.5 Classification of Oncogene-Targeted Drugs by Drug-Delivery Presentation
1.5.1 Overview: Global Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation: 2021 Versus 2025 Versus 2032
1.5.2 Global Oncogene-Targeted Drugs Consumption Value Market Share by Drug-Delivery Presentation in 2025
1.5.3 Bottle Presentation
1.5.4 Blister Presentation
1.5.5 Vial Presentation
1.5.6 Ampoule Presentation
1.5.7 Prefilled Syringe Presentation
1.5.8 Cartridge Presentation
1.5.9 Infusion Bag Presentation
1.6 Global Oncogene-Targeted Drugs Market by Application
1.6.1 Overview: Global Oncogene-Targeted Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Clinic
1.6.3 Hospital
1.6.4 Others
1.7 Global Oncogene-Targeted Drugs Market Size & Forecast
1.8 Global Oncogene-Targeted Drugs Market Size and Forecast by Region
1.8.1 Global Oncogene-Targeted Drugs Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Oncogene-Targeted Drugs Market Size by Region, (2021-2032)
1.8.3 North America Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.4 Europe Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.6 South America Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Oncogene-Targeted Drugs Product and Solutions
2.1.4 Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Johnson & Johnson Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Oncogene-Targeted Drugs Product and Solutions
2.2.4 Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Roche Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Oncogene-Targeted Drugs Product and Solutions
2.3.4 Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Oncogene-Targeted Drugs Product and Solutions
2.4.4 AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly Oncogene-Targeted Drugs Product and Solutions
2.5.4 Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Eli Lilly Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Oncogene-Targeted Drugs Product and Solutions
2.6.4 Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Bristol Myers Squibb
2.7.1 Bristol Myers Squibb Details
2.7.2 Bristol Myers Squibb Major Business
2.7.3 Bristol Myers Squibb Oncogene-Targeted Drugs Product and Solutions
2.7.4 Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Bristol Myers Squibb Recent Developments and Future Plans
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer Oncogene-Targeted Drugs Product and Solutions
2.8.4 Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Bayer Recent Developments and Future Plans
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business
2.9.3 Takeda Oncogene-Targeted Drugs Product and Solutions
2.9.4 Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Takeda Recent Developments and Future Plans
2.10 Amgen
2.10.1 Amgen Details
2.10.2 Amgen Major Business
2.10.3 Amgen Oncogene-Targeted Drugs Product and Solutions
2.10.4 Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Amgen Recent Developments and Future Plans
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business
2.11.3 Boehringer Ingelheim Oncogene-Targeted Drugs Product and Solutions
2.11.4 Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Boehringer Ingelheim Recent Developments and Future Plans
2.12 Daiichi Sankyo
2.12.1 Daiichi Sankyo Details
2.12.2 Daiichi Sankyo Major Business
2.12.3 Daiichi Sankyo Oncogene-Targeted Drugs Product and Solutions
2.12.4 Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Daiichi Sankyo Recent Developments and Future Plans
2.13 Hengrui
2.13.1 Hengrui Details
2.13.2 Hengrui Major Business
2.13.3 Hengrui Oncogene-Targeted Drugs Product and Solutions
2.13.4 Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Hengrui Recent Developments and Future Plans
2.14 Hansoh
2.14.1 Hansoh Details
2.14.2 Hansoh Major Business
2.14.3 Hansoh Oncogene-Targeted Drugs Product and Solutions
2.14.4 Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Hansoh Recent Developments and Future Plans
2.15 Betta
2.15.1 Betta Details
2.15.2 Betta Major Business
2.15.3 Betta Oncogene-Targeted Drugs Product and Solutions
2.15.4 Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Betta Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Oncogene-Targeted Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Oncogene-Targeted Drugs by Company Revenue
3.2.2 Top 3 Oncogene-Targeted Drugs Players Market Share in 2025
3.2.3 Top 6 Oncogene-Targeted Drugs Players Market Share in 2025
3.3 Oncogene-Targeted Drugs Market: Overall Company Footprint Analysis
3.3.1 Oncogene-Targeted Drugs Market: Region Footprint
3.3.2 Oncogene-Targeted Drugs Market: Company Product Type Footprint
3.3.3 Oncogene-Targeted Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Oncogene-Targeted Drugs Consumption Value and Market Share by Type (2021-2026)
4.2 Global Oncogene-Targeted Drugs Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global Oncogene-Targeted Drugs Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
6.2 North America Oncogene-Targeted Drugs Market Size by Application (2021-2032)
6.3 North America Oncogene-Targeted Drugs Market Size by Country
6.3.1 North America Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
6.3.2 United States Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
6.3.3 Canada Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
6.3.4 Mexico Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
7.2 Europe Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
7.3 Europe Oncogene-Targeted Drugs Market Size by Country
7.3.1 Europe Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
7.3.2 Germany Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.3 France Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.5 Russia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.6 Italy Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Oncogene-Targeted Drugs Market Size by Region
8.3.1 Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Region (2021-2032)
8.3.2 China Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.3 Japan Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.4 South Korea Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.5 India Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.7 Australia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
9.2 South America Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
9.3 South America Oncogene-Targeted Drugs Market Size by Country
9.3.1 South America Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
9.3.2 Brazil Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
9.3.3 Argentina Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Oncogene-Targeted Drugs Market Size by Country
10.3.1 Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
10.3.2 Turkey Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
10.3.4 UAE Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Oncogene-Targeted Drugs Market Drivers
11.2 Oncogene-Targeted Drugs Market Restraints
11.3 Oncogene-Targeted Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Oncogene-Targeted Drugs Industry Chain
12.2 Oncogene-Targeted Drugs Upstream Analysis
12.3 Oncogene-Targeted Drugs Midstream Analysis
12.4 Oncogene-Targeted Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oncogene-Targeted Drugs by Type
1.3.1 Overview: Global Oncogene-Targeted Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Oncogene-Targeted Drugs Consumption Value Market Share by Type in 2025
1.3.3 Axitinib (Inlyta)
1.3.4 Ponatinib (Iclusig)
1.3.5 Imatinib (Gleevec)
1.3.6 Sunitinib (Sutent)
1.3.7 Pazopanib (Votrient)
1.3.8 Dabrafenib (Tafinlar)
1.3.9 Vandetanib (Caprelsa)
1.3.10 Vemurafenib (Zelboraf)
1.3.11 Cabozantinib (Cabometyx and Cometriq)
1.4 Classification of Oncogene-Targeted Drugs by Manufacturing Process
1.4.1 Overview: Global Oncogene-Targeted Drugs Market Size by Manufacturing Process: 2021 Versus 2025 Versus 2032
1.4.2 Global Oncogene-Targeted Drugs Consumption Value Market Share by Manufacturing Process in 2025
1.4.3 Chemical Synthesis Product
1.4.4 Semi-Synthetic Product
1.4.5 Recombinant Expression Product
1.4.6 Cell-Culture Derived Product
1.4.7 Enzymatic Synthesis Product
1.4.8 Oligonucleotide Solid-Phase Synthesis Product
1.4.9 Conjugation Process Product
1.5 Classification of Oncogene-Targeted Drugs by Drug-Delivery Presentation
1.5.1 Overview: Global Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation: 2021 Versus 2025 Versus 2032
1.5.2 Global Oncogene-Targeted Drugs Consumption Value Market Share by Drug-Delivery Presentation in 2025
1.5.3 Bottle Presentation
1.5.4 Blister Presentation
1.5.5 Vial Presentation
1.5.6 Ampoule Presentation
1.5.7 Prefilled Syringe Presentation
1.5.8 Cartridge Presentation
1.5.9 Infusion Bag Presentation
1.6 Global Oncogene-Targeted Drugs Market by Application
1.6.1 Overview: Global Oncogene-Targeted Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Clinic
1.6.3 Hospital
1.6.4 Others
1.7 Global Oncogene-Targeted Drugs Market Size & Forecast
1.8 Global Oncogene-Targeted Drugs Market Size and Forecast by Region
1.8.1 Global Oncogene-Targeted Drugs Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Oncogene-Targeted Drugs Market Size by Region, (2021-2032)
1.8.3 North America Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.4 Europe Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.6 South America Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Oncogene-Targeted Drugs Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Oncogene-Targeted Drugs Product and Solutions
2.1.4 Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Johnson & Johnson Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Oncogene-Targeted Drugs Product and Solutions
2.2.4 Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Roche Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Oncogene-Targeted Drugs Product and Solutions
2.3.4 Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Oncogene-Targeted Drugs Product and Solutions
2.4.4 AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly Oncogene-Targeted Drugs Product and Solutions
2.5.4 Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Eli Lilly Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Oncogene-Targeted Drugs Product and Solutions
2.6.4 Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Bristol Myers Squibb
2.7.1 Bristol Myers Squibb Details
2.7.2 Bristol Myers Squibb Major Business
2.7.3 Bristol Myers Squibb Oncogene-Targeted Drugs Product and Solutions
2.7.4 Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Bristol Myers Squibb Recent Developments and Future Plans
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer Oncogene-Targeted Drugs Product and Solutions
2.8.4 Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Bayer Recent Developments and Future Plans
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business
2.9.3 Takeda Oncogene-Targeted Drugs Product and Solutions
2.9.4 Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Takeda Recent Developments and Future Plans
2.10 Amgen
2.10.1 Amgen Details
2.10.2 Amgen Major Business
2.10.3 Amgen Oncogene-Targeted Drugs Product and Solutions
2.10.4 Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Amgen Recent Developments and Future Plans
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business
2.11.3 Boehringer Ingelheim Oncogene-Targeted Drugs Product and Solutions
2.11.4 Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Boehringer Ingelheim Recent Developments and Future Plans
2.12 Daiichi Sankyo
2.12.1 Daiichi Sankyo Details
2.12.2 Daiichi Sankyo Major Business
2.12.3 Daiichi Sankyo Oncogene-Targeted Drugs Product and Solutions
2.12.4 Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Daiichi Sankyo Recent Developments and Future Plans
2.13 Hengrui
2.13.1 Hengrui Details
2.13.2 Hengrui Major Business
2.13.3 Hengrui Oncogene-Targeted Drugs Product and Solutions
2.13.4 Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Hengrui Recent Developments and Future Plans
2.14 Hansoh
2.14.1 Hansoh Details
2.14.2 Hansoh Major Business
2.14.3 Hansoh Oncogene-Targeted Drugs Product and Solutions
2.14.4 Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Hansoh Recent Developments and Future Plans
2.15 Betta
2.15.1 Betta Details
2.15.2 Betta Major Business
2.15.3 Betta Oncogene-Targeted Drugs Product and Solutions
2.15.4 Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Betta Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Oncogene-Targeted Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Oncogene-Targeted Drugs by Company Revenue
3.2.2 Top 3 Oncogene-Targeted Drugs Players Market Share in 2025
3.2.3 Top 6 Oncogene-Targeted Drugs Players Market Share in 2025
3.3 Oncogene-Targeted Drugs Market: Overall Company Footprint Analysis
3.3.1 Oncogene-Targeted Drugs Market: Region Footprint
3.3.2 Oncogene-Targeted Drugs Market: Company Product Type Footprint
3.3.3 Oncogene-Targeted Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Oncogene-Targeted Drugs Consumption Value and Market Share by Type (2021-2026)
4.2 Global Oncogene-Targeted Drugs Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global Oncogene-Targeted Drugs Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
6.2 North America Oncogene-Targeted Drugs Market Size by Application (2021-2032)
6.3 North America Oncogene-Targeted Drugs Market Size by Country
6.3.1 North America Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
6.3.2 United States Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
6.3.3 Canada Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
6.3.4 Mexico Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
7.2 Europe Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
7.3 Europe Oncogene-Targeted Drugs Market Size by Country
7.3.1 Europe Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
7.3.2 Germany Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.3 France Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.5 Russia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
7.3.6 Italy Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Oncogene-Targeted Drugs Market Size by Region
8.3.1 Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Region (2021-2032)
8.3.2 China Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.3 Japan Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.4 South Korea Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.5 India Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
8.3.7 Australia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
9.2 South America Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
9.3 South America Oncogene-Targeted Drugs Market Size by Country
9.3.1 South America Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
9.3.2 Brazil Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
9.3.3 Argentina Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Oncogene-Targeted Drugs Market Size by Country
10.3.1 Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Country (2021-2032)
10.3.2 Turkey Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
10.3.4 UAE Oncogene-Targeted Drugs Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Oncogene-Targeted Drugs Market Drivers
11.2 Oncogene-Targeted Drugs Market Restraints
11.3 Oncogene-Targeted Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Oncogene-Targeted Drugs Industry Chain
12.2 Oncogene-Targeted Drugs Upstream Analysis
12.3 Oncogene-Targeted Drugs Midstream Analysis
12.4 Oncogene-Targeted Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Oncogene-Targeted Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Oncogene-Targeted Drugs Consumption Value by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Table 3. Global Oncogene-Targeted Drugs Consumption Value by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Table 4. Global Oncogene-Targeted Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Oncogene-Targeted Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Oncogene-Targeted Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 8. Johnson & Johnson Major Business
Table 9. Johnson & Johnson Oncogene-Targeted Drugs Product and Solutions
Table 10. Johnson & Johnson Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Johnson & Johnson Recent Developments and Future Plans
Table 12. Roche Company Information, Head Office, and Major Competitors
Table 13. Roche Major Business
Table 14. Roche Oncogene-Targeted Drugs Product and Solutions
Table 15. Roche Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Roche Recent Developments and Future Plans
Table 17. Pfizer Company Information, Head Office, and Major Competitors
Table 18. Pfizer Major Business
Table 19. Pfizer Oncogene-Targeted Drugs Product and Solutions
Table 20. Pfizer Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. AstraZeneca Company Information, Head Office, and Major Competitors
Table 22. AstraZeneca Major Business
Table 23. AstraZeneca Oncogene-Targeted Drugs Product and Solutions
Table 24. AstraZeneca Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. AstraZeneca Recent Developments and Future Plans
Table 26. Eli Lilly Company Information, Head Office, and Major Competitors
Table 27. Eli Lilly Major Business
Table 28. Eli Lilly Oncogene-Targeted Drugs Product and Solutions
Table 29. Eli Lilly Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Eli Lilly Recent Developments and Future Plans
Table 31. Novartis Company Information, Head Office, and Major Competitors
Table 32. Novartis Major Business
Table 33. Novartis Oncogene-Targeted Drugs Product and Solutions
Table 34. Novartis Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Novartis Recent Developments and Future Plans
Table 36. Bristol Myers Squibb Company Information, Head Office, and Major Competitors
Table 37. Bristol Myers Squibb Major Business
Table 38. Bristol Myers Squibb Oncogene-Targeted Drugs Product and Solutions
Table 39. Bristol Myers Squibb Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Bristol Myers Squibb Recent Developments and Future Plans
Table 41. Bayer Company Information, Head Office, and Major Competitors
Table 42. Bayer Major Business
Table 43. Bayer Oncogene-Targeted Drugs Product and Solutions
Table 44. Bayer Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Bayer Recent Developments and Future Plans
Table 46. Takeda Company Information, Head Office, and Major Competitors
Table 47. Takeda Major Business
Table 48. Takeda Oncogene-Targeted Drugs Product and Solutions
Table 49. Takeda Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Takeda Recent Developments and Future Plans
Table 51. Amgen Company Information, Head Office, and Major Competitors
Table 52. Amgen Major Business
Table 53. Amgen Oncogene-Targeted Drugs Product and Solutions
Table 54. Amgen Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Amgen Recent Developments and Future Plans
Table 56. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 57. Boehringer Ingelheim Major Business
Table 58. Boehringer Ingelheim Oncogene-Targeted Drugs Product and Solutions
Table 59. Boehringer Ingelheim Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Boehringer Ingelheim Recent Developments and Future Plans
Table 61. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 62. Daiichi Sankyo Major Business
Table 63. Daiichi Sankyo Oncogene-Targeted Drugs Product and Solutions
Table 64. Daiichi Sankyo Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Daiichi Sankyo Recent Developments and Future Plans
Table 66. Hengrui Company Information, Head Office, and Major Competitors
Table 67. Hengrui Major Business
Table 68. Hengrui Oncogene-Targeted Drugs Product and Solutions
Table 69. Hengrui Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Hengrui Recent Developments and Future Plans
Table 71. Hansoh Company Information, Head Office, and Major Competitors
Table 72. Hansoh Major Business
Table 73. Hansoh Oncogene-Targeted Drugs Product and Solutions
Table 74. Hansoh Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Hansoh Recent Developments and Future Plans
Table 76. Betta Company Information, Head Office, and Major Competitors
Table 77. Betta Major Business
Table 78. Betta Oncogene-Targeted Drugs Product and Solutions
Table 79. Betta Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Betta Recent Developments and Future Plans
Table 81. Global Oncogene-Targeted Drugs Revenue (USD Million) by Players (2021-2026)
Table 82. Global Oncogene-Targeted Drugs Revenue Share by Players (2021-2026)
Table 83. Breakdown of Oncogene-Targeted Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 84. Market Position of Players in Oncogene-Targeted Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 85. Head Office of Key Oncogene-Targeted Drugs Players
Table 86. Oncogene-Targeted Drugs Market: Company Product Type Footprint
Table 87. Oncogene-Targeted Drugs Market: Company Product Application Footprint
Table 88. Oncogene-Targeted Drugs New Market Entrants and Barriers to Market Entry
Table 89. Oncogene-Targeted Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 90. Global Oncogene-Targeted Drugs Consumption Value (USD Million) by Type (2021-2026)
Table 91. Global Oncogene-Targeted Drugs Consumption Value Share by Type (2021-2026)
Table 92. Global Oncogene-Targeted Drugs Consumption Value Forecast by Type (2027-2032)
Table 93. Global Oncogene-Targeted Drugs Consumption Value by Application (2021-2026)
Table 94. Global Oncogene-Targeted Drugs Consumption Value Forecast by Application (2027-2032)
Table 95. North America Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 96. North America Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 97. North America Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 98. North America Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 99. North America Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 100. North America Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 101. Europe Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 102. Europe Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 103. Europe Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 104. Europe Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 105. Europe Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 106. Europe Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 107. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 108. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 109. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 110. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 111. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 112. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 113. South America Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 114. South America Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 115. South America Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 116. South America Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 117. South America Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 118. South America Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 120. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 121. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 122. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 123. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 124. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 125. Global Key Players of Oncogene-Targeted Drugs Upstream (Raw Materials)
Table 126. Global Oncogene-Targeted Drugs Typical Customers
Table 1. Global Oncogene-Targeted Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Oncogene-Targeted Drugs Consumption Value by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Table 3. Global Oncogene-Targeted Drugs Consumption Value by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Table 4. Global Oncogene-Targeted Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Oncogene-Targeted Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Oncogene-Targeted Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 8. Johnson & Johnson Major Business
Table 9. Johnson & Johnson Oncogene-Targeted Drugs Product and Solutions
Table 10. Johnson & Johnson Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Johnson & Johnson Recent Developments and Future Plans
Table 12. Roche Company Information, Head Office, and Major Competitors
Table 13. Roche Major Business
Table 14. Roche Oncogene-Targeted Drugs Product and Solutions
Table 15. Roche Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Roche Recent Developments and Future Plans
Table 17. Pfizer Company Information, Head Office, and Major Competitors
Table 18. Pfizer Major Business
Table 19. Pfizer Oncogene-Targeted Drugs Product and Solutions
Table 20. Pfizer Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. AstraZeneca Company Information, Head Office, and Major Competitors
Table 22. AstraZeneca Major Business
Table 23. AstraZeneca Oncogene-Targeted Drugs Product and Solutions
Table 24. AstraZeneca Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. AstraZeneca Recent Developments and Future Plans
Table 26. Eli Lilly Company Information, Head Office, and Major Competitors
Table 27. Eli Lilly Major Business
Table 28. Eli Lilly Oncogene-Targeted Drugs Product and Solutions
Table 29. Eli Lilly Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Eli Lilly Recent Developments and Future Plans
Table 31. Novartis Company Information, Head Office, and Major Competitors
Table 32. Novartis Major Business
Table 33. Novartis Oncogene-Targeted Drugs Product and Solutions
Table 34. Novartis Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Novartis Recent Developments and Future Plans
Table 36. Bristol Myers Squibb Company Information, Head Office, and Major Competitors
Table 37. Bristol Myers Squibb Major Business
Table 38. Bristol Myers Squibb Oncogene-Targeted Drugs Product and Solutions
Table 39. Bristol Myers Squibb Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Bristol Myers Squibb Recent Developments and Future Plans
Table 41. Bayer Company Information, Head Office, and Major Competitors
Table 42. Bayer Major Business
Table 43. Bayer Oncogene-Targeted Drugs Product and Solutions
Table 44. Bayer Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Bayer Recent Developments and Future Plans
Table 46. Takeda Company Information, Head Office, and Major Competitors
Table 47. Takeda Major Business
Table 48. Takeda Oncogene-Targeted Drugs Product and Solutions
Table 49. Takeda Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Takeda Recent Developments and Future Plans
Table 51. Amgen Company Information, Head Office, and Major Competitors
Table 52. Amgen Major Business
Table 53. Amgen Oncogene-Targeted Drugs Product and Solutions
Table 54. Amgen Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Amgen Recent Developments and Future Plans
Table 56. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 57. Boehringer Ingelheim Major Business
Table 58. Boehringer Ingelheim Oncogene-Targeted Drugs Product and Solutions
Table 59. Boehringer Ingelheim Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Boehringer Ingelheim Recent Developments and Future Plans
Table 61. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 62. Daiichi Sankyo Major Business
Table 63. Daiichi Sankyo Oncogene-Targeted Drugs Product and Solutions
Table 64. Daiichi Sankyo Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Daiichi Sankyo Recent Developments and Future Plans
Table 66. Hengrui Company Information, Head Office, and Major Competitors
Table 67. Hengrui Major Business
Table 68. Hengrui Oncogene-Targeted Drugs Product and Solutions
Table 69. Hengrui Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Hengrui Recent Developments and Future Plans
Table 71. Hansoh Company Information, Head Office, and Major Competitors
Table 72. Hansoh Major Business
Table 73. Hansoh Oncogene-Targeted Drugs Product and Solutions
Table 74. Hansoh Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Hansoh Recent Developments and Future Plans
Table 76. Betta Company Information, Head Office, and Major Competitors
Table 77. Betta Major Business
Table 78. Betta Oncogene-Targeted Drugs Product and Solutions
Table 79. Betta Oncogene-Targeted Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Betta Recent Developments and Future Plans
Table 81. Global Oncogene-Targeted Drugs Revenue (USD Million) by Players (2021-2026)
Table 82. Global Oncogene-Targeted Drugs Revenue Share by Players (2021-2026)
Table 83. Breakdown of Oncogene-Targeted Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 84. Market Position of Players in Oncogene-Targeted Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 85. Head Office of Key Oncogene-Targeted Drugs Players
Table 86. Oncogene-Targeted Drugs Market: Company Product Type Footprint
Table 87. Oncogene-Targeted Drugs Market: Company Product Application Footprint
Table 88. Oncogene-Targeted Drugs New Market Entrants and Barriers to Market Entry
Table 89. Oncogene-Targeted Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 90. Global Oncogene-Targeted Drugs Consumption Value (USD Million) by Type (2021-2026)
Table 91. Global Oncogene-Targeted Drugs Consumption Value Share by Type (2021-2026)
Table 92. Global Oncogene-Targeted Drugs Consumption Value Forecast by Type (2027-2032)
Table 93. Global Oncogene-Targeted Drugs Consumption Value by Application (2021-2026)
Table 94. Global Oncogene-Targeted Drugs Consumption Value Forecast by Application (2027-2032)
Table 95. North America Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 96. North America Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 97. North America Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 98. North America Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 99. North America Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 100. North America Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 101. Europe Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 102. Europe Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 103. Europe Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 104. Europe Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 105. Europe Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 106. Europe Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 107. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 108. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 109. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 110. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 111. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 112. Asia-Pacific Oncogene-Targeted Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 113. South America Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 114. South America Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 115. South America Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 116. South America Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 117. South America Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 118. South America Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 120. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 121. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 122. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 123. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 124. Middle East & Africa Oncogene-Targeted Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 125. Global Key Players of Oncogene-Targeted Drugs Upstream (Raw Materials)
Table 126. Global Oncogene-Targeted Drugs Typical Customers
LIST OF FIGURES
Figure 1. Oncogene-Targeted Drugs Picture
Figure 2. Global Oncogene-Targeted Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Oncogene-Targeted Drugs Consumption Value Market Share by Type in 2025
Figure 4. Axitinib (Inlyta)
Figure 5. Ponatinib (Iclusig)
Figure 6. Imatinib (Gleevec)
Figure 7. Sunitinib (Sutent)
Figure 8. Pazopanib (Votrient)
Figure 9. Dabrafenib (Tafinlar)
Figure 10. Vandetanib (Caprelsa)
Figure 11. Vemurafenib (Zelboraf)
Figure 12. Cabozantinib (Cabometyx and Cometriq)
Figure 13. Global Oncogene-Targeted Drugs Consumption Value by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Oncogene-Targeted Drugs Consumption Value Market Share by Manufacturing Process in 2025
Figure 15. Chemical Synthesis Product
Figure 16. Semi-Synthetic Product
Figure 17. Recombinant Expression Product
Figure 18. Cell-Culture Derived Product
Figure 19. Enzymatic Synthesis Product
Figure 20. Oligonucleotide Solid-Phase Synthesis Product
Figure 21. Conjugation Process Product
Figure 22. Global Oncogene-Targeted Drugs Consumption Value by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Figure 23. Global Oncogene-Targeted Drugs Consumption Value Market Share by Drug-Delivery Presentation in 2025
Figure 24. Bottle Presentation
Figure 25. Blister Presentation
Figure 26. Vial Presentation
Figure 27. Ampoule Presentation
Figure 28. Prefilled Syringe Presentation
Figure 29. Cartridge Presentation
Figure 30. Infusion Bag Presentation
Figure 31. Global Oncogene-Targeted Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 32. Oncogene-Targeted Drugs Consumption Value Market Share by Application in 2025
Figure 33. Clinic Picture
Figure 34. Hospital Picture
Figure 35. Others Picture
Figure 36. Global Oncogene-Targeted Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 37. Global Oncogene-Targeted Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 38. Global Market Oncogene-Targeted Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 39. Global Oncogene-Targeted Drugs Consumption Value Market Share by Region (2021-2032)
Figure 40. Global Oncogene-Targeted Drugs Consumption Value Market Share by Region in 2025
Figure 41. North America Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 42. Europe Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Asia-Pacific Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. South America Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 45. Middle East & Africa Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 46. Company Three Recent Developments and Future Plans
Figure 47. Global Oncogene-Targeted Drugs Revenue Share by Players in 2025
Figure 48. Oncogene-Targeted Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 49. Market Share of Oncogene-Targeted Drugs by Player Revenue in 2025
Figure 50. Top 3 Oncogene-Targeted Drugs Players Market Share in 2025
Figure 51. Top 6 Oncogene-Targeted Drugs Players Market Share in 2025
Figure 52. Global Oncogene-Targeted Drugs Consumption Value Share by Type (2021-2026)
Figure 53. Global Oncogene-Targeted Drugs Market Share Forecast by Type (2027-2032)
Figure 54. Global Oncogene-Targeted Drugs Consumption Value Share by Application (2021-2026)
Figure 55. Global Oncogene-Targeted Drugs Market Share Forecast by Application (2027-2032)
Figure 56. North America Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 57. North America Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 58. North America Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 59. United States Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. Canada Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Mexico Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Europe Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 63. Europe Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 64. Europe Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 65. Germany Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. France Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. United Kingdom Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. Russia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. Italy Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Asia-Pacific Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 71. Asia-Pacific Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 72. Asia-Pacific Oncogene-Targeted Drugs Consumption Value Market Share by Region (2021-2032)
Figure 73. China Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 74. Japan Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. South Korea Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. India Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Southeast Asia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. Australia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 79. South America Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 80. South America Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 81. South America Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 82. Brazil Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 83. Argentina Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 84. Middle East & Africa Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 85. Middle East & Africa Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 86. Middle East & Africa Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 87. Turkey Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 88. Saudi Arabia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 89. UAE Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 90. Oncogene-Targeted Drugs Market Drivers
Figure 91. Oncogene-Targeted Drugs Market Restraints
Figure 92. Oncogene-Targeted Drugs Market Trends
Figure 93. Porters Five Forces Analysis
Figure 94. Oncogene-Targeted Drugs Industrial Chain
Figure 95. Methodology
Figure 96. Research Process and Data Source
Figure 1. Oncogene-Targeted Drugs Picture
Figure 2. Global Oncogene-Targeted Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Oncogene-Targeted Drugs Consumption Value Market Share by Type in 2025
Figure 4. Axitinib (Inlyta)
Figure 5. Ponatinib (Iclusig)
Figure 6. Imatinib (Gleevec)
Figure 7. Sunitinib (Sutent)
Figure 8. Pazopanib (Votrient)
Figure 9. Dabrafenib (Tafinlar)
Figure 10. Vandetanib (Caprelsa)
Figure 11. Vemurafenib (Zelboraf)
Figure 12. Cabozantinib (Cabometyx and Cometriq)
Figure 13. Global Oncogene-Targeted Drugs Consumption Value by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Oncogene-Targeted Drugs Consumption Value Market Share by Manufacturing Process in 2025
Figure 15. Chemical Synthesis Product
Figure 16. Semi-Synthetic Product
Figure 17. Recombinant Expression Product
Figure 18. Cell-Culture Derived Product
Figure 19. Enzymatic Synthesis Product
Figure 20. Oligonucleotide Solid-Phase Synthesis Product
Figure 21. Conjugation Process Product
Figure 22. Global Oncogene-Targeted Drugs Consumption Value by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Figure 23. Global Oncogene-Targeted Drugs Consumption Value Market Share by Drug-Delivery Presentation in 2025
Figure 24. Bottle Presentation
Figure 25. Blister Presentation
Figure 26. Vial Presentation
Figure 27. Ampoule Presentation
Figure 28. Prefilled Syringe Presentation
Figure 29. Cartridge Presentation
Figure 30. Infusion Bag Presentation
Figure 31. Global Oncogene-Targeted Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 32. Oncogene-Targeted Drugs Consumption Value Market Share by Application in 2025
Figure 33. Clinic Picture
Figure 34. Hospital Picture
Figure 35. Others Picture
Figure 36. Global Oncogene-Targeted Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 37. Global Oncogene-Targeted Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 38. Global Market Oncogene-Targeted Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 39. Global Oncogene-Targeted Drugs Consumption Value Market Share by Region (2021-2032)
Figure 40. Global Oncogene-Targeted Drugs Consumption Value Market Share by Region in 2025
Figure 41. North America Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 42. Europe Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 43. Asia-Pacific Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 44. South America Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 45. Middle East & Africa Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 46. Company Three Recent Developments and Future Plans
Figure 47. Global Oncogene-Targeted Drugs Revenue Share by Players in 2025
Figure 48. Oncogene-Targeted Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 49. Market Share of Oncogene-Targeted Drugs by Player Revenue in 2025
Figure 50. Top 3 Oncogene-Targeted Drugs Players Market Share in 2025
Figure 51. Top 6 Oncogene-Targeted Drugs Players Market Share in 2025
Figure 52. Global Oncogene-Targeted Drugs Consumption Value Share by Type (2021-2026)
Figure 53. Global Oncogene-Targeted Drugs Market Share Forecast by Type (2027-2032)
Figure 54. Global Oncogene-Targeted Drugs Consumption Value Share by Application (2021-2026)
Figure 55. Global Oncogene-Targeted Drugs Market Share Forecast by Application (2027-2032)
Figure 56. North America Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 57. North America Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 58. North America Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 59. United States Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. Canada Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Mexico Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Europe Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 63. Europe Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 64. Europe Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 65. Germany Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. France Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. United Kingdom Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. Russia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. Italy Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Asia-Pacific Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 71. Asia-Pacific Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 72. Asia-Pacific Oncogene-Targeted Drugs Consumption Value Market Share by Region (2021-2032)
Figure 73. China Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 74. Japan Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. South Korea Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. India Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Southeast Asia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. Australia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 79. South America Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 80. South America Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 81. South America Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 82. Brazil Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 83. Argentina Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 84. Middle East & Africa Oncogene-Targeted Drugs Consumption Value Market Share by Type (2021-2032)
Figure 85. Middle East & Africa Oncogene-Targeted Drugs Consumption Value Market Share by Application (2021-2032)
Figure 86. Middle East & Africa Oncogene-Targeted Drugs Consumption Value Market Share by Country (2021-2032)
Figure 87. Turkey Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 88. Saudi Arabia Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 89. UAE Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 90. Oncogene-Targeted Drugs Market Drivers
Figure 91. Oncogene-Targeted Drugs Market Restraints
Figure 92. Oncogene-Targeted Drugs Market Trends
Figure 93. Porters Five Forces Analysis
Figure 94. Oncogene-Targeted Drugs Industrial Chain
Figure 95. Methodology
Figure 96. Research Process and Data Source
